2BROGDEN R N,GOA K L,COUKELL A J.Related articles,links amphotericin-B colloidal dispersion. Areview of its use against systemic fungal infections and visceral leishmaniasis[J].Drugs,1998,56(3):365-383.
3NOSKIN G,PIETRELLI L,GURWITH M,et al.Related articles,links treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients[J]. Bone Marrow Transplant,1999,23(7):697-703.
4吉尔曼.治疗学的药理学基础[M].北京:人民卫生出版社,1998.263.
5Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species[J]. Clin Infect Dis,1995, 20(6): 1526-1530.
6Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS[J]. Clin Infect Dis,1996, 22(2): 315-321.
7Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients[J]. J Antimicrob Chemother, 2002, 49(Suppl S1): 81-86.
8Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three case and review of the literature[J]. Pharmacotherapy , 1998,18(5): 1053 - 1061.
9Roden MM,Nelson LD, Knudsen TA, et al. Trial of acute infusionrelated reactions associated with liposomal amphotericin B:analysis of clinical and epidemiological characteristics[J]. Clin Infect Dis, 2003,36(10): 1213 - 1220.
10Sarosi GA. Amphotericin B:still the ‘gold standard' for antifungal therapy[J]. Postgrad Med, 1990, 88: 151-152, 155-156, 165-166
3Regis AV,Fung J Kusne S Cryptococcosis in organ transplant recipients American Journal of Transplantation,2002,2(7) :575-580
4Shahid H ,Marilyn MW,Nina S Cryptococcus neofomans infection in organ transplant recipients variables influencing clinical characteristics and outcome Emerging infections diseases,2001,7(3):375 - 381
